Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

French advisory body recommends compulsory COVID-19 shots for health workers

Published 07/09/2021, 09:00 PM
Updated 07/10/2021, 06:40 AM
© Reuters. FILE PHOTO: A medical worker prepares a dose of the "Comirnaty" Pfizer-BioNTech COVID-19 vaccine inside the exhibition palace transformed into a vaccination center in Nice as part of the coronavirus disease (COVID-19) vaccination campaign in France, April
PFE
-
AZN
-
MRNA
-

PARIS (Reuters) -France's top health advisory body recommended on Friday that coronavirus vaccinations should be made compulsory without delay for all health workers and other professionals who come into contact with people vulnerable to COVID-19.

The French government closely follows recommendations made by the Haute Autorite de la Sante (HAS), which also advised using mRNA-based Pfizer (NYSE:PFE) or Moderna (NASDAQ:MRNA) vaccines to slow the spread of the highly contagious Delta variant because they offered more protection than other shots.

"While the number of new cases and the pressure on the hospital system remain relatively low, the dynamic of the epidemic in France is significant and could quickly lead to a deterioration in the health situation," HAS said in a statement.

President Emmanuel Macron is expected to address the nation on Monday on the progress of the epidemic and his government's strategy to dampen the impact of what many scientists say is an inevitable fourth wave.

Government officials have said in recent weeks that mandatory vaccination for health workers was being considered as the now-dominant Delta variant causes a sharp upturn in France's infection rate.

On Saturday, the country's National Medicine Academy, a doctors' society, pressed authorities to impose compulsory vaccination for everyone aged 12 and above.

HAS also said the government should start thinking about mandatory vaccination for the entire population, in order to be ready to take such a decision if it became necessary.

The body also recommended shortening the time period between the first and second vaccine doses and said people over 55 who received a first shot of the AstraZeneca (NASDAQ:AZN) vaccine should be given a second dose with an mRNA-based vaccine.

© Reuters. FILE PHOTO: A medical worker prepares a dose of the

After falling from more than 42,000 per day mid-April to less than 2,000 per day in late June, the seven-day average of new infections has been climbing rapidly again since early July.

On Friday, the health ministry registered 4,580 new infections. In the past six days, the seven-day average number of new infections has increased by more than 50% every day, a pattern similar to the early phases of previous waves.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.